Neurocrine to Ask FDA to Begin Reviewing Parkinson’s Therapy Ongentys in 2019
Neurocrine Biosciences will ask the U.S. Food and Drug Administration in early 2019 to begin the regulatory review process that could lead to the approval of its Parkinson’s therapy Ongentys (opicapone). It confirmed the timetable after meeting with FDA officials on its plan to file a New Drug Application for Ongentys,…